{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-038538","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.084310+00:00","generated_at":"2026-06-15T04:00:22.657184+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeuroOne Q2 product revenue surges to $466K; net loss $3.5M; Evo sEEG launched","bullets":["Product revenue $466K in Q2 (vs $37K YoY); collaboration revenue $1.46M first half from Zimmer deal.","Net loss $3.5M for Q2 vs $3.1M prior year; operating expenses rose to $3.5M.","Cash and equivalents $4.6M as of Mar 31, down from $11.1M at Sep 30; no debt.","Commercial launch of Evo sEEG electrode with Zimmer Biomet; first cases at Mayo and Cleveland Clinic.","On track to submit 510(k) for OneRF ablation system in Q2 calendar 2023; new VP of Operations appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-038538","json":"https://secwatch.observer/filing/0001213900-23-038538.json","markdown":"https://secwatch.observer/filing/0001213900-23-038538.md","text":"https://secwatch.observer/filing/0001213900-23-038538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390023038538/0001213900-23-038538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390023038538/ea178248-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:00:22.657184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61591251397f5c364e8e1247d07ac500b7e9a362","claim":"NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal second quarter 2023 ended March 31, 2023 results: revenue product revenue was $466,000, net income Net loss was $3.5 million for the fiscal second quarter 2023.","evidence_excerpt":"Product revenue was $466,000 in the fiscal second quarter 2023, compared to product revenue of $37,000 in the fiscal second quarter 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390023038538/0001213900-23-038538-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter 2023 ended March 31, 2023"},{"label":"Revenue","value":"product revenue was $466,000"},{"label":"Net income","value":"Net loss was $3.5 million for the fiscal second quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}